Add to favorites
Aneel Paulus
Message
Download Resume
Roles available for:
-
Fractional
-
Consulting
-
Contract
-
Interim
-
Jacksonville, Florida, United States
-
Languages:
-
English (US)
English (US)Level: Native
-
English (US)
Achievements
-
Expertise
Translational Oncology Cell therapy & cancer vaccines Preclinical-to-clinical drug development IND-enabling research Multi-omic biomarker science (scRNA-seq, CITE-seq, proteomics, flow / mass cytometry) AI-enabled analytical workflows Phase I/II clinical trial design Medical due diligence & board governance CRO / CDMO partnership management IP & patent strategy Mental health care Integrative medicine & wellness optimization Preventive medicine KOL engagement
Share
Aneel Paulus
Add to favorites
Roles available for:
-
Fractional
-
Consulting
-
Contract
-
Interim
-
Jacksonville, Florida, United States
-
Languages:
-
English (US)
English (US)Level: Native
-
English (US)
Achievements
Why hire me in a fractional role
Experience
Strengths in this role: Scientific strategy & translational judgment · Decisive prioritization across multiple programs · Critical thinking on preclinical → clinical translation and Go/No-Go decisions · Communicating science across scientific, regulatory, IP, business, and board audiences · Coaching & mentoring (10+ trainees now serving as faculty / physicians) · Flexibility and fast context-switching across portfolios · External network across pharma, academia, and biotech.
Industry Group: Health
Industry: Pharmaceuticals
Years of experience: 7 years
Industry Group: Health
Industry: Biotechnology
Years of experience: 3 years
Company name: Alpha2 (Mayo Clinic Spinoff)
Company size: 5 employees
Role in this company: Co-Founder & former CSO of Alpha2 Pharmaceuticals, a Mayo Clinic spinoff biotech. Owned scientific strategy and preclinical → IND-enabling translation of small-molecule scaffolds and an individualized cancer-vaccine concept now being licensed to a new venture partner. Managed CRO and academic-CRO partnerships across medicinal chemistry, IND-enabling studies, CMC and regulatory readiness. Co-inventor on three pending patent applications- one licensed to Alpha2.
Strengths in this role: Patient-centered clinical judgment in mental health · Designing evidence-based multimodal care protocols (functional medicine, ketamine-assisted therapy, accelerated TMS, qEEG-neurofeedback) · Critical thinking on outcome measurement and real-world evidence in non-pharmaceutical care · Communicating complex science compassionately to patients, families, and partners · Coaching clinical teams · Flexibility across mental, somatic, and cognitive domains · Founder operational leadership.
Industry Group: Health
Industry: Mental Health Care
Years of experience: 3 years
Industry Group: Health
Industry: Health, Wellness and Fitness
Years of experience: 1 year
Company name: West Eastern Health
Company size: 6 employees
Role in this company: Founder of West Eastern Health (2024–Present), an integrative mental health and optimization center applying evidence-based non-pharmaceutical protocols — functional medicine, ketamine-assisted therapy, accelerated TMS, and qEEG-neurofeedback — for mental-health treatment, somatic-health support, and cognitive / performance optimization (including cancer survivor population). Set clinical direction, designed protocols, and built outcome-measurement and real-world data infrastructure.
Strengths in this role: Medical & scientific due diligence on clinical-stage cell-therapy programs · Strategic governance and risk–benefit judgment for first-patient treatment decisions · Critical thinking on patient qualification, oversight, and post-treatment care criteria · Coordinating with external clinical investigators (UCLA, Mayo Clinic) on hybrid trial-strategy design · Communicating across CEO, scientific founders, investigators, and external partners · KOL network across oncology, and cell therapy.
Industry Group: Health
Industry: Biotechnology
Years of experience: 2 years
Company name: NKore Biotherapeutics
Company size: 6 employees
Role in this company: Board Director & Medical Advisor (Medical Advisor 2023–Present; Board 2026–Present) at NKore Biotherapeutics, a clinical-stage immuno-oncology company developing NK101 — an allogeneic, genetically unaltered NK-cell therapy built on 35+ years of UCLA research. Conduct medical due diligence on first-patient treatments; set criteria for patient qualification, clinical oversight, and post-treatment care; coordinate hybrid trial-strategy design with external investigators at Mayo Clinic.
-
Board membership
Company: NKore Biotherapeutics
Position: Board of Directors, Member
From: 05/08/2026
To: Present
-
Degrees & accreditations
Medical Doctorate (MD)
Master of Science (Translational Oncology & Interdisciplinary Sciences)
-
Membership & affiliations
American Society of Hematology
American Society of Clinical Oncology
American Association for Cancer Research
-
Success story
As Medical Advisor (2023) and now Board Director (2026) at NKore Biotherapeutics, I helped take NK101 — an allogeneic, genetically unaltered NK-cell therapy — from patient 1 to patient 17 in an ex-U.S. GMP-approved facility and clinic. I designed the medical due-diligence, patient-qualification, clinical-oversight, and post-treatment-care framework that scaled with the cohort (no reported adverse events). NKore is filing an IND for a formal U.S. Phase I/II clinical trial later this year.
